ASTRAZENECA PHARMACEUTICALS LP v. AMNEAL PHARMACEUTICALS, LLC
3:12-cv-04841
Overview
Parties
Defendant
ASTRAZENECA PHARMACEUTICALS LP NPE (Individual / Inventor)
Represented By
3 Attorneys ListedPlaintiff
ASTRAZENECA UK LIMITED NPE (University / Research)
Represented By
3 Attorneys ListedCounter Claimant
AMNEAL PHARMACEUTICALS CO. INDIA PRIVATE LIMITED NPE (University / Research)
Represented By
1 Attorneys ListedCourt & Judges
Court
District Court, D. New Jersey (njd)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 2 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 5,948,437 A Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 1,881,696 P | US Continuation / Sibling | View Official Patent → |
ASTRAZENECA PHARMACEUTICALS LP v. ANCHEN PHARMACEUTICALS, INC.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US5948437
Pharmaceutical compositions using thiazepine
|
Filed: 1997-05-28
Issued: 1999-09-07
|
Expired (Term Ended)
Expires: 2017-05-28
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term — No obviousness-type double patenting truncation noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).